Utilization and Advantages of Dimer & Trimer Capping Reagents
This catalog demonstrates the applications and advantages of Dimer & Trimer Capping reagents listed herein. Dimer and Trimer Caps are utilized as building blocks in the block coupling method for oligonucleotide (nucleic acid) synthesis, particularly in RNA synthesis, providing several important benefits.
Inquire About This Product
basic information
For inquiries regarding quantity, quality, etc., please contact us.
Price information
It varies depending on the synthesis scale. Please contact us.
Delivery Time
Applications/Examples of results
Application Methods - RNA Oligonucleotide Synthesis: Used as phosphoramidite blocks for dinucleotides and trinucleotides. - Improvement of Solid-Phase Synthesis Efficiency: These blocks are used instead of monomers when elongating oligonucleotide chains in solid-phase synthesis. - Large-Scale Synthesis of siRNA: Suitable for more efficient and large-scale synthesis of oligonucleotides that are potential therapeutic candidates, such as siRNA (small interfering RNA). - Construction of Mutation Libraries: Trimer phosphoramidites (codon amidites) are used to synthesize oligonucleotides based on specific amino acid codons, enabling fully controlled randomization without codon bias or frameshift mutations. Advantages 1. Reduction and Acceleration of Steps By coupling multiple units at once, the total number of steps required to synthesize the desired RNA sequence is significantly reduced. 2. Improved Purity and Yield Minimization of n-1 dimer formation can be achieved. 3. Easier Purification Separation of products from short impurity sequences is simplified.
catalog（1）
Download All Catalogs
Company information
Ayurveda is well-known, but historically, India has been significantly involved with "medicine." Sapala Organics was established in 2005 in Hyderabad, located in the central part of the Deccan Plateau. The state government is actively investing to make this area a "Pharma City" (a treasure trove of medicine). Sapala has gained recognition from major pharmaceutical companies in the United States and Europe, steadily achieving results. To further provide the technological capabilities developed globally to Japan, Sapala Corporation was established in February 2018 as a local subsidiary in Japan. Recently, the Japanese government has also been focusing on projects that promote advanced pharmaceutical development and drug discovery, including nucleic acid-related drugs. We encourage you to consider the technological expertise of "Sapala," which excels in these fields.
